acetylsalicylic acid N-oxysuccinimide ester | 84388-73-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: acetylsalicylic acid N-oxysuccinimide ester
• 英文别名: Acetylsalicylsaeure-N-hydroxysuccinimidester；acetylsalicylic acid N-hydroxysuccinimide ester；2,5-Pyrrolidinedione, 1-[[2-(acetyloxy)benzoyl]oxy]-；(2,5-dioxopyrrolidin-1-yl) 2-acetyloxybenzoate
• CAS: 84388-73-8
• 化学式: C₁₃H₁₁NO₆
• 分子量: 277.233
• InChiKey: SVLOWSQZBNSVQV-UHFFFAOYSA-N

物化性质

• 熔点：
  80 °C
• 沸点：
  425.2±47.0 °C(Predicted)
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  90
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  acetylsalicylic acid N-oxysuccinimide ester 在 乙醇 、 sodium 、 sodium hydride 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 27.0h， 生成 4-hydroxy-3-methoxycarbonylcoumarin
  参考文献：
  名称：

  Functionalized 4-Hydroxy Coumarins: Novel Synthesis, Crystal Structure and DFT Calculations

  摘要：

  一种新的短步骤方法学已被开发用于功能化香豆素的高产率合成，该方法从N-羟基琥珀酰亚胺酯的O-乙酰水杨酸作为活化前体开始。该过程基于在温和反应条件下进行的串联C-酰化-环化反应。3-甲氧羰基-4-羟基香豆素的结构已通过X射线衍射分析确定，并通过DFT计算优化参数与其几何结构进行了比较。

  DOI：

  10.3390/molecules16010384
• 作为产物：
  描述：

  N-羟基丁二酰亚胺 以80%的产率得到
  参考文献：
  名称：

  SINGH, PRITPAL;HINGORANI, L. L.;TRIVEDI, G. K., INDIAN J. CHEM. B , 29,(1990) N, C. 551-555

  摘要：

  DOI：

文献信息

• Synthesis and anti-inflammatory activity of acetylsalicylamino acids and peptides
  作者：Sh. Kh. Khalikov、M. Kodirov、S. V. Alieva

  DOI：10.1007/s10600-006-0079-5

  日期：2006.3

  Several water-soluble acetylsalicylamino acids and peptides containing neutral and acidic amino acids were synthesized and investigated for anti-inflammatory activity.

  合成了若干种含水溶性乙酰水杨酰的氨基酸及中性和酸性氨基酸的肽，并对其抗炎活性进行了研究。
• Mimetics of the Arg-Gly-Asp Sequence: Synthesis and Studies of the Antiaggregative Properties
  作者：O. V. Gribovskaya、V. P. Martinovich、E. V. Rodko、E. D. Rasyuk、T. V. Ryabtseva、V. P. Golubovich

  DOI：10.1134/s106816202106008x

  日期：2021.11

  It is known that the Arg-Gly-Asp sequence in the fibrinogen molecule is key in binding to the receptors on the surface of platelets. We searched for the compounds which were able to inhibit the binding and synthesized the following analogs of this sequence: 2-acetoxybenzoyl-Arg-βAla-Asp, 4-piperidinecarbonyl-βAla-Asp, and 4-aminobezoyl-βAla-Asp. These compounds were shown to inhibit the platelets aggregation in a different degree. The 2-acetoxybenzoyl-Arg-βAla-Asp analog demonstrated the highest inhibitory activity. A decrease in the expression of the CD62p and CD63 markers on platelets was also found after the action of the Arg-Gly-Asp analogs, confirming the ability of these compounds to block the fibrinogen binding sites for the GP IIb/IIIa glycoprotein receptors.

  摘要 众所周知，纤维蛋白原分子中的 Arg-Gly-Asp 序列是与血小板表面受体结合的关键。我们寻找了能够抑制该序列结合的化合物，并合成了该序列的以下类似物：2-乙酰氧基苯甲酰基-Arg-βAla-Asp、4-哌啶甲酰基-βAla-Asp 和 4-aminobezoyl-βAla-Asp 。这些化合物对血小板聚集有不同程度的抑制作用。2-acetoxybenzoyl-Arg-βAla-Asp 类似物的抑制活性最高。在 Arg-Gly-Asp 类似物的作用下，血小板上的 CD62p 和 CD63 标志物的表达也有所下降，这证实了这些化合物能够阻断纤维蛋白原与 GP IIb/IIIa 糖蛋白受体的结合位点。
• Use of endothelin conjugates in therapy, new endothelin conjugates, agents that contain the latter, and process for their production
  申请人：——

  公开号：US20030119719A1

  公开（公告）日：2003-06-26

  This invention relates to the use of conjugates that consist of endothelins and active groups for therapy of vascular diseases as well as new endothelin conjugates, agents that contain these compounds and process for their production.

  本发明涉及使用由内皮素和活性基团组成的共轭物治疗血管疾病，以及新的内皮素共轭物，包含这些化合物的制剂和它们的生产过程。
• CYCLOPEPTIDE DERIVATIVES
  申请人：——

  公开号：US20020032306A1

  公开（公告）日：2002-03-14

  The invention relates to compounds of the formula (I) R1 Q1 XQ2 R2, in which: Q1, Q2, each independent of one another, are missing or are NH(CH2)n CO; R1, R2, each independent of one another, are missing or are cyclo(ArgGlyAspZ), wherein Z is missing in the side chain of Q1 or Q2 or if Q1 and/or Q2 are missing, is bound to X, at least one of the groups R1 or R2 always having to be included; X is COR 18 CO, and if R1 Q1 or R2 Q2 are missing is R10, R13, R16, HetCO or a fluorescent pigment residue linked through a CONH, COO, NHC (═S)NH, NHC(═O)NH, SO2 NH or NHCO bond; and Z, R10, R13, R16, R18, Het and n have the meanings given in claim 1. The invention also relates to the salts of said compounds. Said compounds and their salts can be used as integrin inhibitors, in particular for the prevention and treatment of circulatory diseases, thrombosis, heart infarct, coronary heart diseases, arteriosclerosis, angiogenic diseases and in tumor therapy.

  本发明涉及式(I)的化合物，其中：Q1，Q2，互相独立，可以缺失或为NH(CH2)n CO; R1，R2，互相独立，可以缺失或为环状(ArgGlyAspZ)，其中Z在Q1或Q2的侧链中缺失或如果Q1和/或Q2缺失，则与X结合，其中必须始终包括R1或R2中的至少一个基团; X为COR 18 CO，如果R1 Q1或R2 Q2缺失，则为R10，R13，R16，HetCO或通过CONH、COO、NHC(═S)NH、NHC(═O)NH、SO2 NH或NHCO键连接的荧光色素残基; Z，R10，R13，R16，R18，Het和n的含义如权利要求书中所述。本发明还涉及所述化合物的盐。所述化合物及其盐可用作整合素抑制剂，特别用于预防和治疗循环疾病、血栓、心肌梗塞、冠心病、动脉硬化、血管生成性疾病和肿瘤治疗。
• Singh; Hingorani; Trivedi, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1990, vol. 29, # 6, p. 551 - 555
  作者：Singh、Hingorani、Trivedi

  DOI：——

  日期：——